Dynasty Wealth Management LLC Acquires 3,249 Shares of AstraZeneca PLC (NASDAQ:AZN)

Dynasty Wealth Management LLC lifted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 27.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 15,261 shares of the company’s stock after purchasing an additional 3,249 shares during the period. Dynasty Wealth Management LLC’s holdings in AstraZeneca were worth $1,122,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Verdence Capital Advisors LLC raised its stake in AstraZeneca by 20.9% during the 1st quarter. Verdence Capital Advisors LLC now owns 39,301 shares of the company’s stock worth $2,889,000 after acquiring an additional 6,793 shares during the period. Mayflower Financial Advisors LLC bought a new stake in AstraZeneca during the 1st quarter worth approximately $204,000. Victory Capital Management Inc. raised its stake in AstraZeneca by 8.4% during the 1st quarter. Victory Capital Management Inc. now owns 438,193 shares of the company’s stock worth $32,207,000 after acquiring an additional 34,123 shares during the period. Bridgewater Advisors Inc. bought a new stake in AstraZeneca during the 1st quarter worth approximately $729,000. Finally, Larson Financial Group LLC raised its stake in AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock worth $28,000 after acquiring an additional 289 shares during the period. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Down 1.2%

Shares of AZN opened at $69.26 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $87.68. The company has a 50 day simple moving average of $70.75 and a two-hundred day simple moving average of $70.90. The firm has a market cap of $214.80 billion, a P/E ratio of 27.82, a price-to-earnings-growth ratio of 1.29 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. During the same period last year, the firm posted $2.06 EPS. The company’s revenue was up 7.2% on a year-over-year basis. On average, equities analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on AZN. BNP Paribas initiated coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They set an “outperform” rating and a $75.00 target price on the stock. Berenberg Bank set a $97.00 price objective on shares of AstraZeneca in a report on Wednesday, July 9th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $89.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.